Insider Trading Alert - BSQR, MNR And MDRX Traded By Insiders

Yesterday, March 16, 2016, 100 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $51.12 to $7,757,838.42.

Highlighted Stocks Traded by Insiders:

Bsquare (BSQR) - FREE Research Report

Chase Jerry D, who is President & CEO at Bsquare, bought 3,500 shares at $5.74 on March 16, 2016. Following this transaction, the President & CEO owned 73,272 shares meaning that the stake was boosted by 5.02% with the 3,500-share transaction.

The shares most recently traded at $5.89, up $0.15, or 2.59% since the insider transaction. Historical insider transactions for Bsquare go as follows:

  • 4-Week # shares bought: 2,500
  • 4-Week # shares sold: 14,648
  • 12-Week # shares bought: 5,500
  • 12-Week # shares sold: 14,648
  • 24-Week # shares bought: 5,500
  • 24-Week # shares sold: 14,648

The average volume for Bsquare has been 92,800 shares per day over the past 30 days. Bsquare has a market cap of $68.3 million and is part of the technology sector and computer software & services industry. Shares are down 4.93% year-to-date as of the close of trading on Wednesday.

BSQUARE Corporation provides software solutions and related engineering services to companies that develop connected systems in North America, Asia, and Europe. The company has a P/E ratio of 11.5. Currently, there are no analysts who rate Bsquare a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on BSQR - FREE

TheStreet Quant Ratings rates Bsquare as a hold. The company's strengths can be seen in multiple areas, such as its solid stock price performance, largely solid financial position with reasonable debt levels by most measures and notable return on equity. However, as a counter to these strengths, we also find weaknesses including unimpressive growth in net income, weak operating cash flow and poor profit margins. Get the full Bsquare Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Monmouth Real Estate Investment (MNR) - FREE Research Report

Umh Properties, Inc., who is Shareholder at Monmouth Real Estate Investment, bought 13,731 shares at $10.56 on March 16, 2016. Following this transaction, the Shareholder owned 2.2 million shares meaning that the stake was boosted by 0.64% with the 13,731-share transaction.

Miller Kevin S., who is Chief Financial Officer at Monmouth Real Estate Investment, bought 95 shares at $10.56 on March 16, 2016. Following this transaction, the Chief Financial Officer owned 36,728 shares meaning that the stake was boosted by 0.26% with the 95-share transaction.

The shares most recently traded at $11.35, up $0.79, or 6.96% since the insider transaction. Historical insider transactions for Monmouth Real Estate Investment go as follows:

  • 4-Week # shares bought: 4,071
  • 12-Week # shares bought: 5,920
  • 24-Week # shares bought: 22,028

The average volume for Monmouth Real Estate Investment has been 246,000 shares per day over the past 30 days. Monmouth Real Estate Investment has a market cap of $712.4 million and is part of the financial sector and real estate industry. Shares are up 6.41% year-to-date as of the close of trading on Wednesday.

Monmouth Real Estate Investment Corporation (MREIC) is a real estate investment trust. It owns, manages, and leases properties to investment-grade tenants on long-term leases. The firm invests in the public equity and real estate markets of the United States. The stock currently has a dividend yield of 5.78%. The company has a P/E ratio of 35.7. Currently, there is 1 analyst who rates Monmouth Real Estate Investment a buy, no analysts rate it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on MNR - FREE

TheStreet Quant Ratings rates Monmouth Real Estate Investment as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, impressive record of earnings per share growth and compelling growth in net income. However, as a counter to these strengths, we find that the company's return on equity has been disappointing. Get the full Monmouth Real Estate Investment Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Allscripts Healthcare Solutions (MDRX) - FREE Research Report

Poulton Richard J., who is President at Allscripts Healthcare Solutions, sold 5,000 shares at $12.85 on March 16, 2016. Following this transaction, the President owned 359,064 shares meaning that the stake was reduced by 1.37% with the 5,000-share transaction.

The shares most recently traded at $12.26, down $0.59, or 4.81% since the insider transaction. Historical insider transactions for Allscripts Healthcare Solutions go as follows:

  • 4-Week # shares bought: 6,500
  • 4-Week # shares sold: 70,000
  • 12-Week # shares bought: 6,500
  • 12-Week # shares sold: 70,000
  • 24-Week # shares bought: 6,500
  • 24-Week # shares sold: 70,000

The average volume for Allscripts Healthcare Solutions has been 2.8 million shares per day over the past 30 days. Allscripts Healthcare Solutions has a market cap of $2.4 billion and is part of the technology sector and computer software & services industry. Shares are down 17.49% year-to-date as of the close of trading on Wednesday.

Allscripts Healthcare Solutions, Inc. provides information technology and services to healthcare organizations in the United States, Canada, and internationally. Currently, there are 10 analysts who rate Allscripts Healthcare Solutions a buy, no analysts rate it a sell, and 12 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on MDRX - FREE

TheStreet Quant Ratings rates Allscripts Healthcare Solutions as a hold. The company's strengths can be seen in multiple areas, such as its solid stock price performance, impressive record of earnings per share growth and compelling growth in net income. However, as a counter to these strengths, we find that the company's return on equity has been disappointing. Get the full Allscripts Healthcare Solutions Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

More from Markets

LIVE BLOG: Cohen Pleads Guilty, Manafort Found Guilty -- Any Market Impact?

LIVE BLOG: Cohen Pleads Guilty, Manafort Found Guilty -- Any Market Impact?

Azealia Banks Confirms Elon Musk Smokes Weed

Azealia Banks Confirms Elon Musk Smokes Weed

Kohl's CEO: Getting Great Feedback From Amazon Partnership

Kohl's CEO: Getting Great Feedback From Amazon Partnership

Coal Stocks Set to Climb as Trump Extends Olive Branch to Miners

Coal Stocks Set to Climb as Trump Extends Olive Branch to Miners

Stocks Trim Gains At Close After S&P 500 Sets Intraday High

Stocks Trim Gains At Close After S&P 500 Sets Intraday High